Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 8/20 | 0.56 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | PRMT3 | O60678 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22752111 | 0.89 | CYP3A4 (0.53) | CYP3A4NAMPTCA12CA9IMPDH2 | |
| SCHEMBL20353542 | 0.89 | CYP3A4 (0.58) | CYP3A4NAMPTCA12CA9IMPDH2 | |
| SCHEMBL20353451 | 0.88 | CYP3A4 (0.55) | CYP3A4NAMPTIMPDH2MAPTMEN1 | |
| SCHEMBL20524931 | 0.87 | CYP3A4 (0.57) | CYP3A4NAMPTCA12CA9IMPDH2 | |
| SCHEMBL20524933 | 0.87 | CYP3A4 (0.57) | CYP3A4NAMPTCA12CA9IMPDH2 | |
| SCHEMBL14124383 | 0.86 | CYP3A4 (0.61) | CYP3A4NAMPTCA12CA9MAPT | |
| SCHEMBL14124381 | 0.84 | KDM4E (0.54) | CYP3A4NAMPTIMPDH2MAPTMEN1 | |
| SCHEMBL14124402 | 0.83 | IMPDH2 (0.64) | CYP3A4NAMPTCA12CA9IMPDH2 | |
| SCHEMBL29258328 | 0.82 | MAPT (0.58) | CYP3A4NAMPTIMPDH2MAPTMEN1 | |
| SCHEMBL29258330 | 0.82 | MAPT (0.58) | CYP3A4NAMPTIMPDH2MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10472327-B2 | 6-aminoisoquinoline compounds | AERIE PHARMACEUTICALS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-20180186746-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | ALCON INC. (CH) | 2018-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10472327-B2 | 6-aminoisoquinoline compounds | COQ8A, PGC, AGK | CYP3A4 2672/4885NAMPT 1188/4885CA12 4860/4885 |
| US-20180186746-A1 | 6-AMINOISOQUINOLINE COMPOUNDS | COQ8A, PGC, AGK | CYP3A4 2672/4885NAMPT 1188/4885CA12 4860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.